Cantor sees strong year ahead for oncology M&A
Written by Emily J. Thompson, Senior Investment Analyst
Source: SeekingAlpha
- Strong Year Ahead for Oncology M&A: Cantor Fitzgerald predicts a strong year for oncology mergers and acquisitions, with a focus on antibody drug conjugates, radiopharmaceuticals, and T-cell engagers.
- Motivation for Deals: Impending patent expirations leading to revenue risks are motivating companies to engage in deals. Oncology products account for a significant portion of the revenue at risk.
- Global Market Growth: The global market for oncology drugs is expected to grow significantly by 2028, surpassing other therapeutic areas in growth rate.
- Acquisition Deals Outlook: Cantor estimates between five and 17 acquisition deals in the industry this year, with three already announced.
- Assets of Interest: Big Pharma will seek de-risked assets with proof-of-concept data, focusing on drug candidates addressing larger markets like breast, lung, or colorectal cancer.
Analyst Views on KPTI
Wall Street analysts forecast KPTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPTI is 13.83 USD with a low forecast of 6.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.660
Low
6.00
Averages
13.83
High
21.00
Current: 6.660
Low
6.00
Averages
13.83
High
21.00
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
